A
Alcista
Alcista · 25%IRMD
$56.90
Precio del escenario
$87.650
-0.614 (-0.70%)Al cierre
Loading chart…
- Máximo
- 88.780
- Apertura
- 88.480
- Precio medio ponderado por volumen
- 87.80
- Volumen
- 79.23K
- Capitalización
- 556.72M
- Mínimo
- 86.980
- Importe
- 6.96M
- EV/EBITDA, TTM
- 31.33
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories, disposables and services. Its MRidium 3870 MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium 3860+ MRI Compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to safely and predictably and other IV fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably on magnetic fields of over 30,000 gauss.
Análisis de IA of IRadimed Corp (IRMD)
MantenerIRadimed Corp (IRMD) is currently priced at $88.27, with a forward P/E ratio of 41.15, indicating a premium valuation. The recent RSI of 55.19 suggests the stock is neither overbought nor oversold, which is neutral for potential buyers. However, the company reported stagnant revenue growth of only 0.5% year-over-year in Q2 2026, which raises concerns about future performance. Additionally, the gross margin has declined to 74% from 78%, reflecting rising production costs. Given these factors, while the stock has potential for growth with upcoming product launches, the current valuation and recent performance metrics suggest it may be prudent to hold rather than buy at this time.
Recomendaciones de analistas (2)
+12.95% de potencial alcista
Comprar
1 Comprar
1 Mantener
0 Vender
Actual: 87.65
Mínimo
98.00
Promedio
99.00
Máximo
100.00
Needham
Mantener
—
2026-09-22
Needham
2026-09-22
Precio objetivo
—
Mantener
Lake Street
Comprar
$120
2026-02-11
Lake Street
2026-02-11
Precio objetivo
$120
Comprar
Roth Capital
Comprar
$120
2026-02-10
Roth Capital
2026-02-10
Precio objetivo
$120
Comprar
Roth Capital
Comprar
$98
2025-11-04
Roth Capital
2025-11-04
Precio objetivo
$98
Comprar
Lake Street
Comprar
$100
2025-11-03
Lake Street
2025-11-03
Precio objetivo
$100
Comprar
Métricas de valoración
El PER previsto actual de IRadimed Corp (IRMD) es 41.15, frente a su media de 5 años de 36.31.
Escenarios de precio de Alphio AI para IRMD
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con IRMD en cartera
Cronología de eventos
Noticias
2.008-08NASDAQ.COMIRadimed (IRMD) Q2 2026 Earnings Call Transcript
9.508-04Yahoo FinanceiRadimed Corp Reports Q2 2026 Earnings Results
8.008-03seekingalphaiRadimed Declares Quarterly Dividend of $0.20
9.508-02NewsfilterAlreadyMAD Corporation Reports Q2 2026 Financial Results with Strong Growth
- 9.507-31seekingalpha
IRadimed Reports Strong Q2 2026 Earnings and Production Growth
Preguntas frecuentes sobre IRMD, respondidas por Alphio AI
IRadimed Corporation develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and accessories, disposables and services. Its MRidium 3870 MRI Compatible IV infusion pump system provides a non-magnetic Intravenous (IV) infusion pump system that is specifically designed for safe use during MRI procedures. Its MRidium 3860+ MRI Compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor with non-ferrous parts and other special features to safely and predictably and other IV fluids during various MRI procedures. Its IRadimed 3880 MRI Compatible patient vital signs monitoring system has been designed with non-magnetic components and other features to safely and accurately during various MRI procedures. The Company sells its products primarily to hospitals and acute care facilities. The IRADIMED 3880 system operates dependably on magnetic fields of over 30,000 gauss. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
IRadimed Corp (IRMD) is currently priced at $88.27, with a forward P/E ratio of 41.15, indicating a premium valuation. The recent RSI of 55.19 suggests the stock is neither overbought nor oversold, which is neutral for potential buyers. However, the company reported stagnant revenue growth of only 0.5% year-over-year in Q2 2026, which raises concerns about future performance. Additionally, the gross margin has declined to 74% from 78%, reflecting rising production costs. Given these factors, while the stock has potential for growth with upcoming product launches, the current valuation and recent performance metrics suggest it may be prudent to hold rather than buy at this time.
2 analysts cover IRMD: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.